References
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.
Vangsted AJ, Klausen TW, Andersen NF, Abildgaard N, Gang AO, Gregersen H, et al. Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004. Eur J Haematol. 2010;85:209–16.
Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016;30:2208–13.
Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant. 2015;50:204–8.
Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant. 2008;42:413–20.
Gimsing P, Holmstrom MO, Klausen TW, Andersen NF, Gregersen H, Pedersen RS, et al. The Danish National Multiple Myeloma Registry. Clin Epidemiol. 2016;8:583–7.
Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–62.
Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, et al. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014;32:2173–80.
Moreau P, de Wit E. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. Br J Haematol. 2017;179:198–218.
Acknowledgements
The work was funded by The Research Fund at Rigshospitalet, Copenhagen, Denmark and The Danish Cancer Society, Copenhagen, Denmark R152-A9822-16-S7.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
41375_2018_57_MOESM1_ESM.docx
Early relapsed disease of multiple myeloma following up-front HDM-ASCT. A study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014
Rights and permissions
About this article
Cite this article
Helm-Petersen, S., Sørrig, R., Klausen, T.W. et al. Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014. Leukemia 32, 2054–2057 (2018). https://doi.org/10.1038/s41375-018-0057-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0057-5
- Springer Nature Limited